Prasco, as GlaxoSmithKline’s (GSK’s) agent and on GSK’s behalf, will solicit orders for, and distribute fluticasone propionate nasal spray to all trade classes in the US under a GSK/Prasco label.
Fluticasone propionate nasal spray is therapeutically equivalent and substitutable for the brand Flonase nasal spray. Fluticasone propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients four years of age and older.
Stan Hull, GSK’s senior vice president of US pharmaceuticals, said: “GSK is always looking for opportunities to increase access to our medicines for patients. The arrangement with Prasco, a known leader in the generics market, allows GSK to expand participation in the generic market in a new way.”